Completed

Positional Cloning of the Gene(s) Responsible for Alagille Syndrome

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Congenital Abnormalities+17

+ Abnormalities, Multiple

+ Aneuploidy

See all eligibility criteria
How is the trial designed

Observational
Study Start: May 1997
See protocol details

Summary

Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 1997

Actual date on which the first participant was enrolled.

The goal of the project is to identify and clone the gene(s) responsible for the Alagille Syndrome (AGS) by a positional cloning approach. The first step towards this goal is to define the smallest genomic candidate region for AGS at 20p12 and to begin to identify genes within this region which are, by definition, candidate genes for the disease. In a collaborative effort with clinician-investigators studying the Alagille syndrome, metaphase chromosomes and genomic DNA from affected individuals will be studied for subchromosomal deletions and for mutations in the candidate genes. Characterization of genes involved in Alagille syndrome could provide important insight into the pathophysiology of the disease, the development of normal liver and treatment of this disease.

NCT00001642
Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

225 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Congenital AbnormalitiesAbnormalities, MultipleAneuploidyBile Duct DiseasesBiliary Tract DiseasesCardiovascular DiseasesCholestasisCholestasis, IntrahepaticChromosome AberrationsDigestive System DiseasesHeart Defects, CongenitalLiver DiseasesMonosomyCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPathologic ProcessesPathological Conditions, Signs and SymptomsCardiovascular AbnormalitiesGenetic Diseases, InbornChromosome DeletionAlagille Syndrome

Criteria

All enrolled affected subjects, whose samples will be analyzed in this study, must meet the criteria for the clinical diagnosis of Alagille Syndrome (Syndromic Bile Duct Paucity) which include liver biopsy findings consistent with Alagille Syndrome and at least 3 of the 5 primary clinical criteria: cholestasis, characteristic face, posterior embryotoxon, "butterfly" vertebrae and cardiac findings.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

National Human Genome Research Institute (NHGRI)

Bethesda, United StatesOpen National Human Genome Research Institute (NHGRI) in Google Maps
CompletedOne Study Center